Loading clinical trials...
Loading clinical trials...
Phase II, Open-label, Randomized, Non-comparative Study Evaluating the Impact of Short Message Service (SMS) on Compliance With Surveillance of Patients With Germ-cell Tumors. (TEXTIS Study)
This study will evaluate the impact of Short Message Service (SMS) on compliance with surveillance of patients with germ-cell tumors. Patients will be randomized in a 2:1 ratio to get 2 groups : (1) patients will receive reminder SMS before appointment detailing the date of consultation and exams to be performed before; (2) standard of care without SMS.
Age
18 - No limit years
Sex
MALE
Healthy Volunteers
No
CHU Besancon
Besançon, Franche-Comté, France
Start Date
February 28, 2019
Primary Completion Date
August 1, 2021
Completion Date
August 1, 2021
Last Updated
March 8, 2019
235
ESTIMATED participants
short message service
OTHER
Lead Sponsor
Centre Hospitalier Universitaire de Besancon
NCT07291258
NCT05157113
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions